Skip to main content

Venous Leg Ulcers

0
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Skye Biologics
Skye BiologicsCA - El Segundo
1 program
E-GRAFT ™N/A1 trial
Active Trials
NCT06764953Recruiting100Est. Dec 2025
Baxter International
1 program
Unite BiomatrixN/A1 trial
Active Trials
NCT00953563Withdrawn0Est. Jul 2011
Baxter
BaxterCosta Rica - Cartago
1 program
Unite BiomatrixN/A
Organogenesis
OrganogenesisCANTON, MA
1 program
ApligrafPHASE_41 trial
Active Trials
NCT02011724Unknown100Est. Jan 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
OrganogenesisApligraf
Skye BiologicsE-GRAFT ™
Baxter InternationalUnite Biomatrix

Clinical Trials (3)

Total enrollment: 200 patients across 3 trials

NCT02011724OrganogenesisApligraf

A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®

Start: Nov 2013Est. completion: Jan 2014100 patients
Phase 4Unknown
NCT06764953Skye BiologicsE-GRAFT ™

Clinical Trial Evaluating an Amnion Membrane Allograft Intended for Use in the Management of Non- Healing Venous Leg Ulcers Versus Standard Of Care Alone

Start: Dec 2024Est. completion: Dec 2025100 patients
N/ARecruiting
NCT00953563Baxter InternationalUnite Biomatrix

The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers

Start: Mar 2009Est. completion: Jul 20110
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 200 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.